Description

Product Overview

Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist (glucose-dependent insulinotropic polypeptide + glucagon-like peptide-1). This dual mechanism makes it one of the most potent metabolic research peptides available, showing enhanced efficacy compared to single-agonist GLP-1 compounds.

Key Benefits

✅ Dual GIP + GLP-1 receptor activation for enhanced metabolic effects
✅ Superior weight management outcomes in comparative research
✅ Improved glycemic control via multiple pathways
✅ Reduced appetite and food intake
✅ Increased insulin sensitivity
✅ Favorable lipid profile improvements
✅ Once-weekly administration protocol

Research Data

Type: Dual GIP/GLP-1 receptor agonist
Half-Life: ~117 hours (5 days)
Molecular Weight: 4,813.5 g/mol
Typical Research Protocol: Start at 2.5mg/week, titrate every 4 weeks
Research Dose Range: 2.5mg to 15mg/week
Administration: Subcutaneous injection once weekly

Storage & Handling

Lyophilized powder: store at -20°C for long-term. After reconstitution, refrigerate at 2-8°C and use within 30 days. Protect from direct light. Use sterile bacteriostatic water for reconstitution.

Stacking Suggestions

Research protocols sometimes combine with low-dose GLP-1 agonists or metabolic peptides like MOTS-c and AOD-9604 for comprehensive metabolic research studies.

Quality Assurance

🔬 HPLC verified >99% purity. Independently tested by ISO 17025 accredited laboratory. Batch-specific Certificate of Analysis available in the Lab Report tab.

Important Notice

⚠️ For laboratory research only. Not a pharmaceutical preparation. Not for human or veterinary use. Handle with appropriate safety equipment and protocols.